In this context, among the molecules capable of targeting TGF-β, it is worth mentioning the humanized anti-TGF-β antibody fresolimumab, which is able to bind and neutralize all three TGF-β isoforms and whose efficacy in reducing TGF-β-mediated gene expression in SSc skin has been described in a small single center study [120]. Here, TGFB1 is linked to systemic sclerosis.